Company intelligence / Profile preview

Mingxin Capital

Yantai, Shandong, China

Ownership: Private
Development stage: Other

Overview

There is no indication that Mingxin Capital is itself a healthcare, life science, biotech, pharma, CRO, or CMO company, nor is there evidence of a significant investment track record in these sectors. It is a generalist growth-stage private equity and venture capital firm focused geographically on China, with experience managing both foreign and domestic funds.

Industry: Investors

Partnerships

Yantai Municipal GovernmentHongda Fund (as co-investors/fund partners)

Beyond the preview

Go deeper on Mingxin Capital.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mingxin Capital.

Explore the full profile